CliffBio
small molecule

TEVETEN

EPROSARTAN MESYLATE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameTEVETEN
Active ingredientEPROSARTAN MESYLATE
StrengthEQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1997
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TEVETEN patent cliff — loss of exclusivity — | CliffBio